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Abstract
Background: Clinical antibiotic prescribing guidelines are essential in defining responsible use in the local context.
Our objective was to investigate the association between adherence to national antibiotic prescribing guidelines
and patient outcomes across a wide range of infectious diseases in hospital inpatients.
Methods: Over five months in 2014, inpatients receiving antibiotics under the care of pulmonary medicine,
infectious diseases and gastroenterology specialties across three university hospitals in Western Norway were
included in this observational cohort study. Patient and antibiotic prescribing data gathered from electronic medical
records included indication for antibiotics, microbiology test results, discharge diagnoses, length of stay (LOS),
comorbidity, estimated glomerular filtration rate (eGFR) on admission and patient outcomes (primary: 30-day
mortality; secondary: in-hospital mortality, 30-day readmission and LOS). Antibiotic prescriptions were classified as
adherent or non-adherent to national guidelines according to documented indication for treatment. Patient
outcomes were analysed according to status for adherence to guidelines using multivariate logistic, linear and
competing risk regression analysis with adjustments made for comorbidity, age, sex, indication for treatment,
seasonality and whether the patient was admitted from an institution or not.
Results: In total, 1756 patients were included in the study. 30-day-mortality and in-hospital mortality were lower
(OR = 0.48, p = 0.003 and OR = 0.46, p = 0.001) in the guideline adherent group, compared to the non-adherent
group. Adherence to guideline did not affect 30-day readmission. In linear regression analysis there was a trend
towards shorter LOS when LOS was analysed for patients discharged alive (predicted mean difference − 0.47, 95%
CI (− 1.02, 0.07), p = 0.081). In competing risk analysis of LOS, the adherent group had a subdistribution hazard ratio
(SHR) of 1.17 95% CI (1.02, 1.34), p = 0.025 for discharge compared to the non-adherent group.
Conclusions: Adhering to antibiotic guidelines when treating infections in hospital inpatients was associated with
favourable patient outcomes in terms of mortality and LOS.
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Background
Antibiotics constitute an important class of medicines,
where the use of a substance has implications beyond
the patient being treated. Antimicrobial stewardship is a
systematic way to improve antibiotic use in hospitals
and has most recently been defined as “a coherent set of
actions which promote using antimicrobials responsibly”
[1]. Clinical guidelines for antibiotic use are essential in
defining responsible use in the local context and are one
of the core elements of stewardship programmes [2].
Studying the association between antibiotic use and pa-
tient outcomes is of great importance and can imply
whether guideline-adherent prescribing practice is safe
and secures equal – or better patient outcome. Most stud-
ies in this field are performed within lower respiratory
tract infections and many are prone to confounding by in-
dication, because patients with less severe illness are more
likely to have received the more narrow-spectrum, guide-
line adherent therapy [3].
Norway has low, but steadily increasing antibiotic re-
sistance rates [4]. Seven months prior to this study, new
national guidelines for antibiotic use in hospitals were
published [5]. We aimed to investigate if appropriate
prescribing practices for hospitalised patients with a
broad spectrum of infectious diseases were associated
with patient outcomes when adjusted for major con-
founding factors.
Methods
Study design and setting
We performed an observational study in the cohort of
patients from a previously published cluster randomized
controlled intervention study, which was performed at
three emergency care and teaching hospitals in Western
Norway [6]. Hospital A and B are tertiary care hospitals
with 1100 and 600 beds, respectively. Hospital C is a
secondary care hospital with 160 beds. Hospital A is in
addition referral hospital for hospitals B and C. Three
medical wards from hospital A and B (infectious dis-
eases, pulmonary medicine and gastroenterology) and
two medical wards from hospital C (infectious diseases/
general medicine and pulmonary/cardiac medicine) were
included in the study. All hospitals were committed to
be using the national guideline for antibiotic use for hos-
pital inpatients [5].
Data collection
Adult patients (over 18 years old) were included in the
study if they received antibiotics for a suspected or con-
firmed infection during admission, were discharged from
a study ward between the 10th of February and the 11th
of July 2014 and had a hospital stay of > 24 h and ≤ 21
days. Minimum length of hospital stay was defined to
assure that included patients were seen by study ward
physicians and maximum length to make manual data
collection throughout the hospital stay feasible. Patients
who either only received antibiotic prophylaxis, had
orthopaedic prosthesis infections or had an indication
for treatment not covered by the national guidelines,
were not included. For patients readmitted during the
study period, only the first stay was included in analysis.
Where data regarding outcome was not possible to re-
trieve (e.g. tourists), or comorbidity data was unavailable,
the patient was excluded. Data were collected manually
from electronic medical records, including admission
notes, medical charts, physician’s notes, discharge letters
and laboratory results. Data included patient demo-
graphics, indication for antibiotic treatment, antibiotic
use, microbiology test results, estimated glomerular fil-
tration rate (eGFR) on admission, length of stay (LOS),
30-day readmission, in-hospital and 30-day mortality,
comorbidity and admittance from- or discharge to insti-
tution. Mortality data was continuously updated within
the electronic medical record, using data from the Nor-
wegian National Registry [7] Supplementary data on
main diagnosis at discharge and comorbidity was re-
trieved by extraction from electronic medical records.
Readmissions were only captured if patients were re-
admitted to the same hospital as the patient was dis-
charged from.
Definitions
All substances comprising the ATC-group “Antibacte-
rials for systemic use” (J01), metronidazole tablets
(P01AB01) and vancomycin tablets (A07AA09) were in-
cluded in the definition of antibiotics for this study [8].
Outcome measures
Primary outcome measure was 30-day mortality, defined
as all-cause mortality during hospital stay or within 30
days of discharge from hospital.
Secondary outcome measures were
a) In-hospital mortality, defined as all-cause in-
hospital mortality during study admission.
b) 30-day readmission, defined as all-cause acute re-
admission to the same study hospital as the patient
was discharged from, within 30 days of discharge,
for patients discharged alive and not transferred to
another hospital.
c) Length of stay, defined as number of days from
admission to discharge for the entire hospital stay
for patients discharged alive, except for time spent
at a hospital rehabilitation centre after discharge
from a study ward. LOS was also analysed for
all patients, with in-hospital mortality as com-
peting risk.
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Study variable
Adherence to national antibiotic guidelines refers to the
choice of active substance(s) for the initial indication for
treatment. Dosing of the substance(s) was not consid-
ered. Adherence was assessed by using syntax in SPSS,
combining the variable for indication for treatment with
the variable for prescribed treatment. Only the
first-choice empirical regimens were regarded adherent.
For patients with antibiotic allergies or kidney failure
where chosen treatment was an alternative guideline
regimen (not first choice), manual adjustment of the ad-
herence variable was performed consistently throughout
the study population. CRB-65-score1 and the severity of
pneumonia were usually not explicitly stated in the pa-
tient notes. Less severe and severe community acquired
pneumonia were therefore assessed together, meaning
that first line treatments for both conditions were con-
sidered adherent. Some patients had more than one
working diagnosis on initiation of therapy. An
ID-physician (BS) reviewed the diagnoses and decided
indication for treatment for these patients, expecting ini-
tial therapy to be based on the most severe working
diagnosis. Infections described as “suspected pneumo-
nia” or “unspecified lower respiratory tract infection” on
admission were assessed for adherence as community-
or hospital acquired pneumonia. A working diagnosis as
“suspected urinary tract infection” (UTI) was assessed as
adherent if treatment was according to guideline treat-
ment for either pyelonephritis or cystitis. For the indica-
tion “suspected pneumonia/UTI”, treatment according
to guideline recommendation for either diagnosis were
considered adherent.
Adjustment variables
Indication for treatment was the indication for first
treatment with antibiotics and was always an infection.
Physicians’ notes were used to identify indication for
treatment and indication was not further assessed for
validity. Indications were grouped into six main categor-
ies (Table 1). Indications which did not fit into the main
categories were included in a seventh category of “Other
infections”. Empirical antibiotic treatment was specific
for each indication and varied within each group.
Comorbidity was defined using the Charlson Comor-
bidity Index (CCI) [9, 10]. For each patient, up to eight
diagnoses were extracted from the hospital electronic
medical record at discharge. All extracted diagnoses
were included in the calculation of CCI, using Stata syn-
tax [11]. Estimated glomerular filtration rate on admis-
sion was originally planned as an adjustment variable,
but as renal disease is included in CCI, this was dis-
carded from analysis. Age was coded in age groups,
starting with patients up to and including the age of
45 and thereafter given in groups of 20 years to the
last group of above 85 years. Admission from an in-
stitution was defined as patients admitted at an in-
stitution with 24/7 care, e.g. another hospital or
nursing home, within 48 h of admission. Adjustment
for seasonality was performed by using the week of
admission as adjustment variable.
Statistics/analysis
To analyse differences in patient characteristics between
the groups with adherent and non-adherent treatment,
we used chi-square test and two-sample t-test for cat-
egorical and continuous data, respectively. Univariate
and multivariate logistic and linear regression were used
to study the association between guideline adherent pre-
scribing practice and patient outcome. Indication for
treatment, comorbidity (CCI), age group, admittance
from institution, sex and seasonality (week of admission)
were evaluated as adjustment variables. Variables that in
univariate regression analysis of 30-day mortality had a
p-value of less than 0.2 (all evaluated variables) were in-
cluded in multivariate analyses for all studied outcomes.
In addition, we used robust variance estimation of re-
gression coefficients to account for clustered observa-
tions on the same hospital ward.
Two sensitivity analyses were performed for 30-day
mortality. In the first, grouping of indication for treatment
was replaced by grouped discharge diagnoses as adjust-
ment variable to evaluate whether estimates of association
would change if diagnoses had changed from admission to
discharge. In the second sensitivity analysis, grouping of
indication for treatment was replaced by individual indica-
tions as an adjustment variable to evaluate whether the
grouping of indications could influence the results.
As the linear regression models of LOS did not ac-
count for in-hospital mortality, we also performed a sen-
sitivity analyses for this outcome by fitting a Fine-Gray
model with in-hospital mortality as competing risk. In
this analysis, we report associations as the subdistribu-
tion hazard ratio (SHR) with 95% confidence intervals,
which denotes the magnitude of the relative difference
in the subdistribution hazard function between adherent
and non-adherent groups [12].
A p-value of < 0.05 was considered statistically signifi-
cant for all analyses. Statistical analysis was performed
using Stata SE version 15 (Stata Statistical Software,
College Station, TX, USA).
Results
During the study period, 1783 patients were eligible for
inclusion. We were not able to retrieve comorbidity data
for 22 patients. For 5 patients who were tourists, out-
come data was unavailable. In final analyses, 1756 pa-
tients were therefore included.
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There was a significant difference between the adher-
ent and non-adherent group with regards to the groups
of indication for treatment, with a higher percentage of
LRTI’s in the adherent group and more patients with
GI-infections, UTIs and “other” infections in the
non-adherent group (Table 2). The non-adherent group
also had a higher proportion of patients admitted from
an institution.
Thirty-day mortality and in-hospital mortality was
significantly lower in patients receiving guideline adher-
ent treatment, with an odds ratio (OR) of 0.48, with p =
0.003 for 30-day mortality and OR = 0.46, with p = 0.001
for in-hospital mortality (Table 3).
During admission, 70 patients died and 16 patients
were discharged to another hospital, so in analysis of
30-day readmission and LOS, 1670 patients were in-
cluded (Table 4). There was no evidence of any dif-
ferences in 30-day readmission between patients
receiving guideline adherent treatment or not. Co-
morbidity (CCI) and seasonality (the week of admis-
sion) were the only variables significantly associated
with 30-day readmission. In the linear regression
analysis of LOS, there was a trend towards shorter
LOS when guideline adherent treatment was pre-
scribed at treatment onset (− 0.47 days, p = 0.087)
(Table 4). This result was supported by the compet-
ing risk analyses of LOS in which the adherent
group was associated with a 17% increase in the rate
of discharge, compared with the non-adherent group
(Additional file 1: Table S1; SHR 1.17, 95% CI (1.02,
1.34), p = 0.025).
Other analysis
We performed two sensitivity analyses for 30-day mor-
tality. In the first analysis, grouped indications for
treatment were substituted with grouped discharge diag-
noses, which could be infections or non-infections. The
association between adherent treatment and mortality now
had an OR= 0.51, 95% CI (0.33, 0.80) with p = 0.003 (not
shown in tables). In the second analysis, grouped indica-
tions were substituted with the individual indications in the
regression model. This changed the estimated OR from
0.48 to 0.54, 95% CI (0.30, 0.99), p = 0.045 (not shown in
tables). For the last analysis, model fit was poor for indica-
tions with few patients and no observed mortality. Only
1591 patients were kept in the model for this analysis.
Discussion
The main findings of this study are that adherence to
antibiotic guidelines at initiation of antibiotic therapy is
associated with lower in-hospital- and 30-day mortality
and shorter LOS. Adherence to guidelines was not sig-
nificantly associated with 30-day readmission.
Structure and process indicators can help us evaluate
whether our antibiotic stewardship efforts are moving us
in the right direction [13–16]. A frequently asked ques-
tion is whether behavioural change interventions lead to
more appropriate antibiotic use, often measured as ad-
herence to guidelines or profile of antibiotic consump-
tion [3, 6, 17]. An equally important question is whether
appropriate antibiotic use leads to the desired outcomes,
like reduction in bacterial resistance rates, adverse
events and mortality [3, 18]. Overprescribing outside
guidelines often result from fear for the patients’ well-
being, and are linked to patients who are severely ill or
have an unclear diagnosis [19]. The expectation of clini-
cians’ to change their antibiotic prescribing behaviours
needs to be supported by evidence-based guidelines and
expert advice to reassure clinicians that guideline adher-
ent antibiotic prescribing is safe and effective.
Table 1 Grouping of indications for treatment
Indication for treatment
Lower respiratory tract infections (LRTI) Community acquired pneumonia (normal and severe), healthcare associated pneumonia (normal
and severe), unspecified lower respiratory tract infections, unknown – suspected pneumonia,
aspiration pneumonia, atypical pneumonia, lung abscess, empyema.
Acute exacerbations of chronic obstructive
pulmonary disease (COPD with LRTI)
Patients with COPD, presenting with LRTI (community and healthcare associated)
Sepsis Focus area; lower respiratory tract, urinary tract, unknown focus, soft tissue, abdomen
and catheter.
Skin and soft tissue infections (SSTI) Erysipelas, cellulitis, abscess, other skin and soft tissue infections, mastitis, necrotising soft tissue
infections, postoperative wound infection.
Gastrointestinal tract infections (GI-infections) Helicobacter pylori-infection, gastroenteritis, peritonitis, cholecystitis/cholangitis, Clostridium
difficile (C.Diff).
Urinary tract infections (UTI) UTI – unspecified, pyelonephritis, lower UTI/cystitis, unknown-suspected UTI, catheter
associated UTI.
Other infections Suspected both pneumonia and UTI, meningitis, neutropenic fever, osteomyelitis, tonsillitis,
arthritis, endocarditis, sinusitis/otitis, and infected intravascular catheters
Indications within each group are given in decreasing order of frequency
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Readmission as an outcome measure in relation to
antibiotic prescribing is not frequently reported [18].
Three studies within community acquired pneumonia
show no association between guideline adherence and
30-day readmission, which is in agreement with the find-
ings in this present study [20–22].
Evidence on the association between guideline
adherence and mortality is diverse. Arnold et al. found
that in-hospital mortality in patients receiving
guideline-adherent treatment for community acquired
pneumonia was 8% (95% CI, 7–10%), compared to 17%
(95% CI, 14–20%) in the group of nonadherence [23].
Asadi et al. did not find any effect on mortality
alone when looking at this variable in hospitalised
patients with community acquired pneumonia,
although the composite endpoint of death or
ICU-admissions favoured guideline adherence [24].
In a Danish study of CAP, with similar resistance
rates and treatment guidelines as Norway, Egelund
et al. found that patients treated with guideline ad-
herent penicillin monotherapy had lower CURB-65
score, less comorbidity and less in-hospital mortality
in unadjusted analysis, while no association between
mortality and guideline adherence was found in
Table 2 Patient characteristics and outcome by adherence or non-adherence to guidelines
Non-adherence (N = 667) Adherence (N = 1089) P-value
Patient characteristics
Indication for treatment
LRTI 161 (24.1) 372 (34.2) < 0.001
COPD with LRTI 124 (18.6) 230 (21.1)
Sepsis 111 (16.6) 180 (16.5)
SSTI 72 (10.8) 115 (10.6)
GI-infection 44 (6.6) 34 (3.1)
UTI 80 (12.0) 99 (9.1)
Other infections 75 (11.2) 59 (5.4)
Charlson Comorbidity Index
CCI = 0 240 (36.0) 432 (39.7) 0.083
CCI = 1 212 (31.8) 373 (34.3)
CCI = 2 119 (17.8) 141 (13.0)
CCI = 3 45 (6.8) 65 (6.0)
CCI = 4 24 (3.6) 33 (3.0)
CCI > 4 27 (4.1) 45 (4.1)
Age, mean (std.dev.) 67.3 (18.2) 67.4 (19.1) 0.885
Age
<=45 92 (13.8) 161 (14.8) 0.680
46–65 156 (23.4) 240 (22.0)
66–85 320 (48.0) 508 (46.7)
>85 99 (14.8) 180 (16.5)
Admitted from institution 120 (18.0) 135 (12.4) 0.001
Discharged to institution 182 (29.0) 258 (24.4) 0.090
Sex
Male 352 (52.8) 565 (51.9) 0.717
Female 315 (47.2) 524 (48.1)
Outcome
In-hospital mortality 38 (5.7) 32 (2.9) 0.004
30-day mortality 75 (11.2) 67 (6.2) < 0.001
30-day readmission (n = 623/1047) 140 (22.5) 206 (19.7) 0.173
LOSa, mean (std.dev.) (n = 623/1047) 7.3 (4.4) 6.7 (4.1) 0.004
aLOS = Length of stay. All analysis was performed using chi-square tests, except mean age and LOS which were analysed using two-sample t-test. P-values in
boldface are statistically significant (<0.05)
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adjusted analysis [25]. However, a systematic review
by Schuts et al., including 37 studies, showed that
when empirical therapy was prescribed according to
guidelines, the relative risk reduction of mortality
was 35% [18]. The majority of patients included in
these studies had pulmonary infections. These pa-
tients constituted almost half of our patient mater-
ial. Our findings are coherent with this recent
review, as we found that the odds ratio of
in-hospital and 30-day mortality for the entire
patient material was 0.46 and 0.48, respectively
when guidelines were followed.
LOS was also favourably associated with adherent
treatment in this study. The SHR was 1.17 for pa-
tients with guideline-adherent treatment, meaning
that the rate of discharge was 17% higher for this
group compared to the rate for the non-adherent
group. Although not significant, there was a trend to-
wards shorter LOS when analysed with linear regres-
sion analysis. 0.47 days constitutes 6.8% of the mean
Table 3 Adjusted analysis of the association between guideline adherence, in-hospital and 30-day mortality
All patients In-hospital mortality 30-day mortality
(N = 1756) (n1 = 70) (N = 1756) P (n2 = 142) (N = 1756) P
n (%) n (%) OR (95% CI) n (%) OR (95% CI)
Adherence to guideline
No 667 (38.0) 38 (5.7) 1.00 75 (11.2) 1.00
Yes 1089 (62.0) 32 (2.9) 0.46 (0.29, 0.74) 0.001 67 (6.2) 0.48 (0.29, 0.78) 0.003
Indication for antibiotic treatment
LRTI 533 (30.4) 35 (6.6) 1.00 69 (13.0) 1.00
COPD with LRTI 354 (20.2) 11 (3.1) 0.44 (0.22, 0.86) 0.017 22 (6.2) 0.45 (0.35, 0.59) < 0.001
Sepsis 291 (16.6) 14 (4.8) 0.69 (0.41, 1.15) 0.153 24 (8.3) 0.59 (0.36, 0.97) 0.038
SSTI 187 (10.7) 1 (0.5) 0.12 (0.02, 0.66) 0.015 3 (1.6) 0.17 (0.03, 1.09) 0.061
GI-infection 78 (4.4) 3 (3.9) 0.75 (0.10, 5.72) 0.782 6 (7.7) 0.78 (0.22, 2.80) 0.708
UTI 179 (10.2) 2 (1.1) 0.12 (0.27, 0.55) 0.006 11 (6.2) 0.35 (0.19, 0.63) 0.001
Other infections 134 (7.6) 4 (3.0) 0.35 (0.17, 0.72) 0.004 7 (5.2) 0.29 (0.19, 0.46) < 0.001
Charlson Comorbidity Index
CCI = 0 672 (38.3) 9 (1.3) 1.00 20 (3.0) 1.00
CCI = 1 585 (33.3) 19 (3.3) 1.60 (0.52, 4.86) 0.411 36 (6.2) 1.40 (0.95, 2.04) 0.088
CCI = 2 260 (14.8) 16 (6.2) 2.66 (0.72, 9.83) 0.143 31 (11.9) 2.67 (1.45, 4.90) 0.002
CCI = 3 110 (6.3) 6 (5.5) 2.27 (0.60, 8.60) 0.228 16 (14.6) 3.18 (1.75, 5.78) < 0.001
CCI = 4 57 (3.3) 8 (14.0) 6.39 (1.64, 24.93) 0.008 14 (24.6) 6.79 (3.31, 13.95) < 0.001
CCI > 4 72 (4.1) 12 (16.7) 8.50 (3.80, 19.04) < 0.001 25 (34.7) 12.04 (8.02, 18.08) < 0.001
Age
< =45 253 (14.4) 1 (0.4) 1.00 2 (0.8) 1.00
46–65 396 (22.6) 7 (1.8) 2.35 (0.35, 15.70) 0.376 14 (3.5) 2.40 (0.53, 10.87) 0.257
66–85 828 (47.2) 39 (4.7) 5.42 (0.82, 35.67) 0.079 80 (9.7) 5.61 (1.51, 20.85) 0.010
> 85 279 (15.9) 23 (8.2) 10.13 (0.99, 103.78) 0.051 46 (16.5) 9.81 (1.91, 50.36) 0.006
Admitted from institution
No 1501 (85.5) 46 (3.1) 1.00 88 (5.9) 1.00
Yes 255 (14.5) 24 (9.4) 2.53 (1.45, 4.43) 0.001 54 (21.2) 3.74 (2.69, 5.20) < 0.001
Sex
Male 917 (52.2) 49 (5.3) 1.00 88 (9.6) 1.00
Female 839 (47.8) 21 (2.5) 0.42 (0.28, 0.61) < 0.001 54 (6.4) 0.59 (0.39, 0.90) 0.015
Week of admissiona 0.96 (0.93, 0.99) 0.005 0.96 (0.93, 0.997) 0.031
aAdjustment for seasonality was performed by using the week of admission as adjustment variable
In-hospital – and 30-day mortality was analysed using multivariate, logistic regression analysis with adjustment for clustering at individual sites. All variables are
included in adjusted analysis. P-values in boldface are statistically significant (<0.05)
Wathne et al. Antimicrobial Resistance and Infection Control            (2019) 8:63 Page 6 of 10
LOS for the study population (6.9 days) and 10.9% of
a mean hospital stay in Norway, which is currently
4.3 days for patients outside the psychiatric wards
[26]. The finding is in line with Schuts et al. which
found that LOS was lower in 17 of the 24 included
studies assessing association between adherence to
guideline and LOS, favouring adherence [18]. The
studies included in this review did however mainly in-
clude patients with lower respiratory tract infections,
while our cohort had a large diversity of infectious
diseases, and a maximum LOS of 21 days.
In observational cohort studies, the major limitation
will be the potential for selection bias, in this case
meaning that the patients with less severe illness may
be more likely to receive guideline-adherent treatment
[3]. By adjusting for indication for treatment, comor-
bidity, age, sex and seasonality, we have aimed to re-
duce the chance of confounding, but there could be
differences in severity within each of the groups of
indications, which could explain some of the differ-
ence seen in mortality between the adherent and
non-adherent group. We did not have data on
Table 4 Adjusted analysis of the association between guideline adherence, 30-day readmission and length of stay
All patients 30 day readmission Length of stay
(N = 1670) (N = 346) (N = 1670) P (N = 1670) (N = 1670) P
n (%) n (%) OR (95%CI) Mean (S.D) Coeff. (95% C.I.)
Adherence to guideline
No 623 (37.3) 140 (22.5) 1.00 7.3 (4.4)
Yes 1047 (62.7) 206 (19.7) 0.87 (0.67, 1.14) 0.321 6.7 (4.1) −0.47 (−1.02, 0.07) 0.081
Indication for antibiotic treatment
LRTI 492 (29.5) 100 (20.3) 1.00 7.0 (4.3)
COPD with LRTI 341 (20.4) 88 (25.8) 1.17 (0.80, 1.73) 0.421 6.6 (3.8) −0.79 (−1.65, 0.08) 0.069
Sepsis 275 (16.5) 46 (16.7) 0.81 (0.54, 1.21) 0.303 7.0 (3.9) 0.22 (−0.73, 1.18) 0.605
SSTI 184 (11.0) 29 (15.8) 0.89 (0.62, 1.28) 0.522 6.2 (4.1) −0.17 (−1.44, 1.10) 0.761
GI-infection 75 (4.5) 18 (24.0) 1.26 (0.64, 2.51) 0.503 7.3 (4.2) 0.53 (− 0.75, 1.81) 0.363
UTI 176 (10.5) 43 (24.4) 1.30 (0.85, 2.01) 0.229 7.1 (4.4) 0.10 (−0.74, 0.95) 0.781
Other infections 127 (7.6) 22 (17.3) 0.78 (0.51, 1.18) 0.240 7.5 (5.1) 0.53 (−0.83, 1.89) 0.386
Charlson Comorbidity Index
CCI = 0 656 (39.3) 97 (14.8) 1.00 6.3 (3.9)
CCI = 1 562 (33.7) 117 (20.8) 1.35 (1.03, 1.76) 0.029 6.9 (4.0) 0.60 (−0.32, 1.53) 0.168
CCI = 2 241 (14.4) 73 (30.3) 2.26 (1.46, 3.52) < 0.001 7.3 (4.2) 0.87 (0.06, 1.68) 0.039
CCI = 3 103 (6.2) 27 (26.2) 1.77 (1.12, 2.82) 0.015 7.7 (5.0) 1.30 (−0.79, 3.38) 0.185
CCI = 4 49 (2.9) 16 (32.7) 2.55 (1.73, 3.76) < 0.001 9.1 (5.4) 2.64 (− 0.42, 5.70) 0.081
CCI > 4 59 (3.5) 16 (27.1) 1.88 (0.89, 3.95) 0.098 9.1 (5.2) 2.42 (1.15, 3.69) 0.003
Age
< =45 250 (15.0) 37 (14.8) 1.00 5.7 (4.1)
46–65 387 (23.2) 75 (19.4) 1.07 (0.71, 1.62) 0.743 6.6 (4.0) 0.74 (0.45, 1.03) 0.001
66–85 779 (46.7) 175 (22.5) 1.15 (0.70, 1.90) 0.576 7.3 (4.3) 1.20 (0.58, 1.83) 0.002
> 85 254 (15.2) 59 (23.2) 1.24 (0.62, 2.49) 0.549 7.2 (4.3) 1.00 (−0.19, 2.18) 0.087
Sex
Male 856 (51.3) 182 (21.3) 1.00 6.9 (4.3)
Female 814 (48.7) 164 (20.2) 0.94 (0.81, 1.09) 0.411 6.9 (4.1) 0.02 (−0.64, 0.69) 0.942
Admitted from institution
No 1441 (86.3) 301 (20.9) 1.00 6.8 (4.2)
Yes 229 (13.7) 45 (19.7) 0.85 (0.62, 1.16) 0.307 7.2 (4.5) 0.02 (−0.53, 0.57) 0.938
Week of admissiona 0.98 (0.96, 1.00) 0.040 −0.05 (− 0.09, − 0.002) 0.044
aAdjustment for seasonality was performed by using the week of admission as adjustment variable
All variables are included in adjusted analysis. 30-day readmission and length of stay was analysed using multivariate logistic- and linear regression, respectively
with adjustment for clustering at individual sites. P-values in boldface are statistically significant (<0.05)
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severity score, which could have helped us limit this
factor. The grouping of indications is both a strength
and a limitation. Looking at patient outcome and ad-
herence across some of the most common infections
seen in hospitals, makes the results more
generalizable, but may also be more difficult to inter-
pret. When working diagnosis on initiation of treat-
ment was uncertain (eg “suspected UTI”) or there
were more than one working diagnoses, we assessed
adherence based on the most likely indication for
treatment. Using working diagnoses for this purpose
is limiting the generalizability of the results to indi-
vidual groups of patients with more strict definitions
of diagnoses. It does however reflect the daily chal-
lenge in the clinical setting where decisions about
treatment have to be made before all diagnostic tools
have been applied and results received and indicates
that adhering to the most relevant guideline is a
strength in this situation.
There were more patients admitted from an institution in
the non-adherent group. This may be because patients ad-
mitted from institutions have more co-morbid disease and
therefore present with more challenging diagnoses. Physi-
cians may also consider the risk of resistant pathogens as
higher and therefore prescribe more broad-spectrum
agents. Furthermore, patients admitted from other institu-
tions may already have received first line agents. Patient
characteristics such as age, sex and comorbidity were very
similar between the groups of patients receiving adherent
or non-adherent treatment according to guidelines. The
groups of UTI’s, “other” infections and GI-infections were
however larger in the non-adherent group and LRTIs were
larger in the adherent group. Prescribing for pneumonia
and COPD exacerbations was the focus of the audit with
feedback performed in the study wards in the underlying
intervention study [6]. The mix of patients within the
groups of indications varied to some extent, such as a
higher number of pyelonephritis in the non-adherent group
(38.8%) compared to the adherent group (23.2%) and
higher number of sepsis with abdominal focus in
non-adherent group (4.5%) compared to adherent group
(0.6%). In a sensitivity analysis for 30-day mortality, the
grouped indications were substituted with the individual in-
dications. This only changed the estimated OR slightly, to
0.53. The difference seen between the groups can therefore
not be explained by these factors alone. Another mechan-
ism is of course that treatment recommended in guidelines
is best practice - securing evidence based effective treat-
ment of the infection, while minimizing ecologic effects,
side effects and impact on the microbiotia and therefore is
associated with better patient outcomes than non-adherent
treatment.
We analysed according to the first indication for
treatment, which was usually a working diagnosis on
admission to the hospital. The diagnosis may have
changed during the hospital stay. We therefore did a
sensitivity analysis for 30-day mortality, where indica-
tion for treatment was substituted with discharge
diagnosis. The OR for the association between adher-
ent treatment and mortality only changed slightly,
from 0.48 to 0.51.
Thirty-day readmission was defined as readmissions to
the same hospital that the patient was discharged from.
This could have caused an underestimation of readmis-
sions if the patients were readmitted to other hospitals.
As inclusion of patients were limited to a LOS of a max-
imum of 21 days, the mean LOS may be underestimated.
Adherence to guideline within the group of excluded pa-
tients was not collected and is therefore unknown.
This was a multicentre study with patients included
from three hospitals and three specialties, which in-
creases generalizability. The number of included patients
is also substantial and we adjusted for known risk factors
for morbidity and mortality, such as age, comorbidity
and admittance from an institution. Given that patients
with a LOS longer than 21 days were excluded, this
limits generalizability of the estimate for this outcome.
Norwegian guidelines were developed with broad
involvement of more than 80 clinicians from all over the
country [5, 27]. They are prudent, with mainly
narrow-spectrum antibiotics as first-line empirical treat-
ment [5]. It is of great importance that guidelines consti-
tute best practice, to provide security for both the
patient and the treating clinician, and secures standard-
ized, safe and effective antibiotic treatment, also in the
absence of an infectious diseases specialist.
This study builds on findings in previous studies, indi-
cating that up-to-date, hospital antibiotic guidelines are
safe and are associated with favourable clinical outcomes
for inpatients. Antibiotic guidelines should be developed
and regularly updated to ensure that they always pro-
mote best practice in the treatment of infectious diseases
in the local context. Accurate, structured and
easy-to-access documentation on severity of infections
should be included in the electronic medical record to
secure availability of this data in quality improvement
processes, evaluation of treatment and research.
To be able to control for more factors in analyses, fu-
ture studies should aim to collect information about se-
verity of infections and whether empirical treatment
provided adequate coverage for the individual patients.
Conclusion
Empirical treatment according to guidelines on initiation
of antibiotic therapy is associated with favourable clinical
outcomes, such as in-hospital and 30-day mortality in
our population of hospital inpatients.
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Endnotes
1CRB-65 (Severity assessment for pneumonia: Confu-
sion, raised Respiratory rate, low Blood pressure and age
65 years or more).
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Additional file 1: Table S1. Length of stay analysed with competing
risk analysis (Fine and Gray). (DOCX 19 kb)
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